Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Core Insights - Corcept Therapeutics' stock is experiencing an increase, with a trading volume of 3.06 million shares on Thursday [1] - The ROSELLA Phase 3 trial for relacorilant combined with nab-paclitaxel in treating platinum-resistant ovarian cancer has met its primary endpoint for overall survival [1] Efficacy Data - Patients receiving relacorilant plus nab-paclitaxel showed a 35% reduction in the risk of death compared to those on nab-paclitaxel alone, with a hazard ratio of 0.65 and a p-value of 0.0004 [2] - The median overall survival for patients on the combination therapy was 16.0 months, compared to 11.9 months for those on nab-paclitaxel alone, indicating a 4.1-month improvement [2] - The combination therapy was well-tolerated, maintaining a safety profile consistent with previous data [2][3] Safety Profile - The type, frequency, and severity of adverse events in the combination therapy group were similar to those in the nab-paclitaxel monotherapy group, indicating that relacorilant did not increase the safety burden [3] - Corcept has also reported that the ROSELLA trial met its primary endpoint for improved progression-free survival [3][4] Regulatory Background - In December 2025, the FDA issued a Complete Response Letter regarding the New Drug Application for relacorilant for hypertension secondary to hypercortisolism, indicating the need for additional evidence of effectiveness [5][6] - Despite the FDA acknowledging the success of the pivotal GRACE trial, it concluded that a favorable benefit-risk assessment could not be made without further evidence from Corcept [6] Market Reaction - Following the positive trial results, Corcept Therapeutics shares rose by 19.14%, reaching a price of $43.26 [6]